These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24411037)

  • 21. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study.
    Borrell A; Casals E; Fortuny A; Farre MT; Gonce A; Sanchez A; Soler A; Cararach V; Vanrell JA
    Prenat Diagn; 2004 Jul; 24(7):541-5. PubMed ID: 15300745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
    Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
    Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examination of a first-trimester Down syndrome screening concept on a mix of 11,107 high- and low-risk patients at a private center for prenatal medicine in Germany.
    Schaelike M; Kossakiewicz M; Kossakiewicz A; Schild RL
    Eur J Obstet Gynecol Reprod Biol; 2009 Jun; 144(2):140-5. PubMed ID: 19362411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Maiz N; Valencia C; Kagan KO; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 May; 33(5):512-7. PubMed ID: 19338027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
    Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM
    Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-trimester screening for trisomy 21 using alpha-fetoprotein.
    Bredaki FE; Wright D; Matos P; Syngelaki A; Nicolaides KH
    Fetal Diagn Ther; 2011; 30(3):215-8. PubMed ID: 21952001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
    Kagan KO; Staboulidou I; Cruz J; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Nov; 36(5):542-7. PubMed ID: 20503223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Maternal biochemical screening -- an approach for genetic prevention. part 1. first and second trimester screening].
    Angelova L; Gadancheva V; Konstantinova D; Stoianova M; Hachmerian M; Yakov B; Kremenski I
    Akush Ginekol (Sofiia); 2013; 52(5):8-13. PubMed ID: 24501862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.
    Santorum M; Wright D; Syngelaki A; Karagioti N; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):714-720. PubMed ID: 27549925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D; Abele H; Baker A; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
    Cowans NJ; Stamatopoulou A; Maiz N; Spencer K; Nicolaides KH
    Prenat Diagn; 2009 Jun; 29(6):578-81. PubMed ID: 19288535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
    Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.